AAAAAA

   
Results: 1-25 | 26-40
Results: 1-25/40
A randomized trial of high-dose compared with low-dose omega-3 fatty acidsin severe IgA nephropathy
Authors: Donadio, JV Larson, TS Bergstralh, EJ Grande, JP
Citation: Jv. Donadio et al., A randomized trial of high-dose compared with low-dose omega-3 fatty acidsin severe IgA nephropathy, J AM S NEPH, 12(4), 2001, pp. 791-799
A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy
Authors: Gorman, CA Garrity, JA Fatourechi, V Bahn, RS Petersen, IA Stafford, SL Earle, JD Forbes, GS Kline, RW Bergstralh, EJ Offord, KP Rademacher, DM Stanley, NM Bartley, GB
Citation: Ca. Gorman et al., A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy, OPHTHALMOL, 108(9), 2001, pp. 1523-1534
Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy
Authors: Roberts, WW Bergstralh, EJ Blute, ML Slezak, JM Carducci, M Han, M Epstein, JI Eisenberger, MA Walsh, PC Partin, AW
Citation: Ww. Roberts et al., Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy, UROLOGY, 57(6), 2001, pp. 1033-1037
PSA doubling time as a predictor of clinical progression after biochemicalfailure following radical prostatectomy for prostate cancer
Authors: Roberts, SG Blute, ML Bergstralh, EJ Slezak, JM Zincke, H
Citation: Sg. Roberts et al., PSA doubling time as a predictor of clinical progression after biochemicalfailure following radical prostatectomy for prostate cancer, MAYO CLIN P, 76(6), 2001, pp. 576-581
Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point?
Authors: Amling, CL Bergstralh, EJ Blute, ML Slezak, JM Zincke, H
Citation: Cl. Amling et al., Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point?, J UROL, 165(4), 2001, pp. 1146-1151
Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy
Authors: Blute, ML Bergstralh, EJ Iocca, A Scherer, B Zincke, H
Citation: Ml. Blute et al., Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy, J UROL, 165(1), 2001, pp. 119-125
Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management - A retrospective analysis
Authors: Barry, MJ Albertsen, PC Bagshaw, MA Blute, ML Cox, R Middleton, RG Gleason, DF Zincke, H Bergstralh, EJ Jacobsen, SJ
Citation: Mj. Barry et al., Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management - A retrospective analysis, CANCER, 91(12), 2001, pp. 2302-2314
Risk of prostate carcinoma death in patients with lymph node metastasis
Authors: Cheng, L Zincke, H Blute, ML Bergstralh, EJ Scherer, B Bostwick, DG
Citation: L. Cheng et al., Risk of prostate carcinoma death in patients with lymph node metastasis, CANCER, 91(1), 2001, pp. 66-73
Risk of prostate carcinoma death in patients with lymph node metastasis
Authors: Cheng, L Zincke, H Blute, ML Bergstralh, EJ Scherer, D Bostwick, DG
Citation: L. Cheng et al., Risk of prostate carcinoma death in patients with lymph node metastasis, CANC CYTOP, 91(1), 2001, pp. 66-73
Lung cancer mortality in the Mayo Lung Project: Impact of extended follow-up
Authors: Marcus, PM Bergstralh, EJ Fagerstrom, RM Williams, DE Fontana, R Taylor, WF Prorok, PC
Citation: Pm. Marcus et al., Lung cancer mortality in the Mayo Lung Project: Impact of extended follow-up, J NAT CANC, 92(16), 2000, pp. 1308-1316
Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease
Authors: King, BF Reed, JE Bergstralh, EJ Sheedy, PF Torres, VE
Citation: Bf. King et al., Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease, J AM S NEPH, 11(8), 2000, pp. 1505-1511
Extranodal extension in lymph node-positive prostate cancer
Authors: Cheng, L Pisansky, TM Ramnani, DM Leibovich, BC Cheville, JC Slezak, E Bergstralh, EJ Zincke, H Bostwick, DG
Citation: L. Cheng et al., Extranodal extension in lymph node-positive prostate cancer, MOD PATHOL, 13(2), 2000, pp. 113-118
Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy
Authors: Cheng, L Slezak, J Bergstralh, EJ Myers, RP Zincke, H Bostwick, DG
Citation: L. Cheng et al., Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy, J CL ONCOL, 18(15), 2000, pp. 2862-2868
Adverse events in chronic hemodialysis patients receiving intravenous irondextran - A comparison of two products
Authors: McCarthy, JT Regnier, CE Loebertmann, CL Bergstralh, EJ
Citation: Jt. Mccarthy et al., Adverse events in chronic hemodialysis patients receiving intravenous irondextran - A comparison of two products, AM J NEPHR, 20(6), 2000, pp. 455-462
Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980 to 1997
Authors: Roberts, RO Bergstralh, EJ Lieber, MM Jacobsen, SJ
Citation: Ro. Roberts et al., Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980 to 1997, UROLOGY, 56(5), 2000, pp. 817-822
Patient survival and renal recovery in acute renal failure: Randomized comparison of cellulose acetate and polysulfone membrane dialyzers
Authors: Albright, RC Smelser, JM McCarthy, JT Homburger, HA Bergstralh, EJ Larson, TS
Citation: Rc. Albright et al., Patient survival and renal recovery in acute renal failure: Randomized comparison of cellulose acetate and polysulfone membrane dialyzers, MAYO CLIN P, 75(11), 2000, pp. 1141-1147
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer
Authors: Blute, ML Bergstralh, EJ Partin, AW Walsh, PC Kattan, MW Scardino, PT Montie, JE Pearson, JD Slezak, JM Zincke, H
Citation: Ml. Blute et al., Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer, J UROL, 164(5), 2000, pp. 1591-1595
Long-term hazard of progression after radical prostatectomy for clinicallylocalized prostate cancer: Continued rise of biochemical failure after 5 years
Authors: Amling, CL Blute, ML Bergstralh, EJ Seay, TM Slezak, J Zincke, H
Citation: Cl. Amling et al., Long-term hazard of progression after radical prostatectomy for clinicallylocalized prostate cancer: Continued rise of biochemical failure after 5 years, J UROL, 164(1), 2000, pp. 101-105
Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997
Authors: Roberts, RO Bergstralh, EJ Peterson, NR Bostwick, DG Lieber, MM Jacobsen, SJ
Citation: Ro. Roberts et al., Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997, J UROL, 163(5), 2000, pp. 1471-1475
Benefit of adjuvant radiation therapy for localized prostate cancer with apositive surgical margin
Authors: Leibovich, BC Engen, DE Patterson, DE Pisansky, TM Alexander, EE Blute, ML Bergstralh, EJ Zincke, H
Citation: Bc. Leibovich et al., Benefit of adjuvant radiation therapy for localized prostate cancer with apositive surgical margin, J UROL, 163(4), 2000, pp. 1178-1182
Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma
Authors: Sato, K Qian, JQ Slezak, JM Lieber, MM Bostwick, DG Bergstralh, EJ Jenkins, RB
Citation: K. Sato et al., Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma, J NAT CANC, 91(18), 1999, pp. 1574-1580
The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial
Authors: Donadio, JV Grande, JP Bergstralh, EJ Dart, RA Larson, TS Spencer, DC
Citation: Jv. Donadio et al., The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial, J AM S NEPH, 10(8), 1999, pp. 1772-1777
Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy
Authors: Cheng, L Cheville, JC Pisansky, TM Sebo, TJ Slezak, J Bergstralh, EJ Neumann, RM Singh, R Pacelli, A Zincke, H Bostwick, DG
Citation: L. Cheng et al., Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy, AM J SURG P, 23(7), 1999, pp. 803-808
Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma
Authors: Gettman, MT Pacelli, A Slezak, J Bergstralh, EJ Blute, M Zincke, H Bostwick, DG
Citation: Mt. Gettman et al., Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma, UROLOGY, 54(3), 1999, pp. 479-485
Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy
Authors: Ghavamian, R Blute, ML Bergstralh, EJ Slezak, J Zincke, H
Citation: R. Ghavamian et al., Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy, UROLOGY, 54(1), 1999, pp. 105-110
Risultati: 1-25 | 26-40